In the news
Mobile Health – Who Pays?
11 February 2011
Mobile health (mHealth) offerings promise to improve healthcare delivery and provide revenue for service providers – but adoption and monetizing the opportunity will require changes to the way the industry does business.
China's Contractor Shine Losing Luster
6 September 2010 — FiercePharma Manufacturing
Ops strategists need to think of their suppliers in China as an extension of their network rather than low-cost country sources, A.T. Kearney consultants say.
In the eye of the beholder: of values & value - 2
5 November 2009 — eyeforpharma.com
Pharma Expert Contributor, Fatima Moncrieffe, explores the concept of value in the pharmaceutical industry, referring to A.T. Kearney's research and experts, who explain that the current U.S. debate is a critical issue for the entire world.
Pharma at the tipping point III: From R&D to markets
5 November 2009 — eyeforpharma.com
A.T. Kearney research shows that one of the most fundamental problems for pharma companies is that much of the industry's R&D efforts focus on therapy areas that are not particularly important to payers and aren't targeted at mass market solutions.
Pharma at the tipping point II: Emerging markets
21 October 2009 — eyeforpharma.com
Healthcare demand is shifting rapidly toward the developing world, where 96% of global population growth is expected over the next 50 years. For pharmas faced with pricing pressures in developed markets, emerging markets will become too attractive to continue to ignore, and pharmas, AT Kearney says, will need to establish prices in a way that maximizes revenue over a drug’s entire lifecycle and across global markets.
Pharma at the tipping point I: Price versus value
21 October 2009 — eyeforpharma.com
Why is the industry operating on the precipice? AT Kearney observes that even as healthcare budgets are rising, drug sales in most developed countries are forecast to be flat. Pricing pressures are increasing globally, and even the normally safe haven of the US has become a challenging market. The problems, AT Kearney says, are symptoms of a shift in the nature of healthcare systems.
Pharmaceuticals out of Balance: Reaching the Tipping Point
21 September 2009 — A.T. Kearney
A.T. Kearney presents evidence that the current pharmaceutical model may become irrelevant in the context of 21st century’s global healthcare needs. With the current dialogue on healthcare reform and the healthcare system in urgent need of restructuring, there is a commensurate impact on the pharmaceutical industry.
 The tipping point that could spell disaster for big pharma
17 September 2009 — Pharma Television
Interview with Jonathan Anscombe.
Select topic from menu on right.
White Paper addresses pharma model
16 September 2009 — PMLive
Management consultant firm, A T Kearney, has highlighted key areas of the pharma model that it believes must be addressed for future success... These relate to what the industry sells, to whom, and how it must be organised.
Pharma “has now reached three tipping points”
16 September 2009 — PharmaTimes
Healthcare is currently out of balance and so therefore is the pharmaceutical industry, as its fortunes are driven by healthcare systems, virtually all of which are now restructuring, says a new report.
Pharmaceuticals: Reaching the Tipping Point
14 September 2009 — www.atkearney.com
There is a danger that the current pharmaceutical model may become irrelevant in the context of 21st century’s global healthcare needs. Healthcare is out of balance and, therefore, so is the pharmaceutical industry. The fortunes of the pharmaceutical industry are driven by the healthcare systems it serves – and virtually every healthcare system is restructuring.
Cancer team takes top Innovation Award
25 April 2008 — Kable
An IT project supporting the fight against cancer has won the big prize at the Government Computing Awards for Innovation 2008.
|